Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD — Stella

Recruiting

Back to Chronic Graft Versus Host Disease trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

Duke, Durham, North Carolina

Key details

Phase

Early testing

Sponsor

Stefanie Sarantopoulos, MD, PhD.

Collaborators

Incyte Corporation, Rigel Pharmaceuticals

Enrollment target

~30 participants

Started

October 2025

Primary completion

January 2029

Age range

18 Years – 80 Years

Last updated January 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov